Overview

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2019-05-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine recommended Phase 2 dose [RP2D]) and the objective response rate of JNJ-42756493 (erdafitinib) in advanced hepatocellular carcinoma (HCC) participants with fibroblast growth factor (FGF) 19 amplification.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC